Sirona Biochem Announces Start of Clinical Trial for Anti-Aging Compound TFC-1326
VANCOUVER, British Columbia, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is...
Month: December 2022
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months
DATA PRESENTED AT THE 2022 AMERICAN ACADEMY OF OPTOMETRY MEETINGMEIBOMIAN GLAND FUNCTION IMPROVES BY 63% AND DRY EYE SYMPTOMS REDUCED...
SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a...
T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Therapy
LEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens...
Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE
Expands Commercialization Efforts in Areas with High Unmet NeedsIRVINE, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA)...
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a...
Alio Raises $18M in First Close of Series C Financing
Closing out a year marked by milestone achievements, including FDA clearance, Alio announces its latest round of fundingBROOMFIELD, Colo., Dec....
Transformation and Technology Expert Timothy Wilde Joins UpHealth as Chief Technology Officer
DELRAY BEACH, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Healthcare transformation expert Timothy Wilde has joined UpHealth, Inc. (NYSE: UPH) as...
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™
Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company...
AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases
The Company will Provide an Overview of its Immune Checkpoint Enhancer (ICE) Platform Clinical Proof-of-Concept Data from its First Generation...
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
iCAD features Solis Mammography in upcoming “ProFound Insights, ProFound Impact” webinar
Solis Mammography’s Chief Medical Officer Chirag Parghi, MD, to share clinical experience and real-world case studies demonstrating clinical value of...
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
Company also announces that Julia Haller, MD, is stepping down from its Board of DirectorsNEW YORK, Dec. 08, 2022 (GLOBE...
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for...
Corcept Therapeutics Provides Miricorilant Clinical Development Update
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement
ATLANTA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is...
MIMEDX Announces Wound & Surgical Product Pipeline Expansion via In-Licensing and Distribution Agreement with Turn Therapeutics
Agreement provides MIMEDX with exclusive rights to Turn’s PermaFusion® proprietary antimicrobial intellectual property (IP), accelerating the product development pipeline for...
Study Published in “Military Medicine” Reports 88% Success Treating Obstructive Sleep Apnea Patients with Precision Oral Appliance Therapy
Treatment with Precision Oral Appliance Therapy Demonstrated Significant Improvements in Apnea-Hypopnea Events, Respiratory Disturbances, Oxygen Saturation, REM Sleep, Sleep Efficiency...
Remix Therapeutics to Present at 5th Annual RNA-Targeted Drug Discovery Summit
Company to Announce Lead Program During Podium PresentationCAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a biotechnology...